Charles Schwab
CALA

Charles Schwab’s Calithera Biosciences, Inc CALA Stock Holding History

Charles Schwab’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,318
Closed -$31K – 3652
2021
Q4 		$31K Hold
2,318
– – ﹤0.01% 3546
2021
Q3 		$102K Buy
2,318
+1,148
+98% +$49.5K ﹤0.01% 3379
2021
Q2 		$49K Sell
1,170
-7,284
-86% -$320K ﹤0.01% 3377
2021
Q1 		$410K Buy
8,454
+463
+6% +$26.9K ﹤0.01% 3142
2020
Q4 		$785K Hold
7,991
– – ﹤0.01% 2845
2020
Q3 		$552K Sell
7,991
-268
-3% -$23.4K ﹤0.01% 2848
2020
Q2 		$873K Buy
8,259
+1,184
+17% +$141K ﹤0.01% 2660
2020
Q1 		$629K Buy
7,075
+939
+15% +$112K ﹤0.01% 2637
2019
Q4 		$701K Buy
6,136
+713
+13% +$53.6K ﹤0.01% 2709
2019
Q3 		$336K Buy
5,423
+1,231
+29% +$98.5K ﹤0.01% 2944
2019
Q2 		$327K Buy
4,192
+327
+8% +$37.1K ﹤0.01% 2983
2019
Q1 		$522K Buy
3,865
+324
+9% +$34K ﹤0.01% 2750
2018
Q4 		$285K Buy
3,541
+294
+9% +$29K ﹤0.01% 2954
2018
Q3 		$341K Sell
3,247
-200
-6% -$19K ﹤0.01% 2968
2018
Q2 		$345K Sell
3,447
-2,850
-45% -$323K ﹤0.01% 2917
2018
Q1 		$794K Buy
6,297
+685
+12% +$107K ﹤0.01% 2593
2017
Q4 		$938K Buy
5,612
+2,032
+57% +$520K ﹤0.01% 2528
2017
Q3 		$1.13M Hold
3,580
– – ﹤0.01% 2474
2017
Q2 		$1.06M Buy
3,580
+2,555
+249% +$683K ﹤0.01% 2432
2017
Q1 		$237K Buy
+1,025
New +$177K ﹤0.01% 2899
2016
Q2 		– Sell
-950
Closed -$108K – 3152
2016
Q1 		$108K Hold
950
– – ﹤0.01% 2983
2015
Q4 		$146K Hold
950
– – ﹤0.01% 3012
2015
Q3 		$104K Hold
950
– – ﹤0.01% 3031
2015
Q2 		$136K Buy
950
+385
+68% +$89.3K ﹤0.01% 3031
2015
Q1 		$186K Hold
565
– – ﹤0.01% 2968
2014
Q4 		$229K Buy
+565
New +$148K ﹤0.01% 2947

Other funds holding CALA

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Charles Schwab's CALA Position: Q1 2022 in Review

Charles Schwab sold out of Calithera Biosciences, Inc (CALA) in Q1 2022, closing a stake of 2,318 shares — an estimated $31K sold.

Charles Schwab first reported a position in CALA in Q4 2014 and held it in 26 quarters. The position peaked at $1.13M in Q3 2017. 54 funds tracked by Wall St. Rank hold CALA as of Q1 2022.

  • Charles Schwab reported no remaining Calithera Biosciences, Inc position as of Q1 2022 after selling out during the quarter.
  • Charles Schwab sold 2,318 Calithera Biosciences, Inc shares in Q1 2022, an estimated $31K.
  • Charles Schwab first reported a position in Calithera Biosciences, Inc in Q4 2014 and held it in 26 quarters.
  • Charles Schwab's Calithera Biosciences, Inc position peaked at $1.13M in Q3 2017.
  • 54 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q1 2022.

Based on Charles Schwab's 13F filing for Q1 2022, filed 13 May 2022.